{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004942","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.421112+00:00","generated_at":"2026-05-28T03:32:29.603028+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Fulcrum expects ~$240M cash at year-end 2024 (preliminary)","bullets":["Expects approximately $240M in cash, equivalents and marketable securities as of Dec 31, 2024 (preliminary, unaudited).","Full Q4 and FY2024 financial results not yet finalized; audit ongoing.","Updated corporate presentation published on January 13, 2025 on company website."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004942","json":"https://secwatch.observer/filing/0001193125-25-004942.json","markdown":"https://secwatch.observer/filing/0001193125-25-004942.md","text":"https://secwatch.observer/filing/0001193125-25-004942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312525004942/0001193125-25-004942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312525004942/d714885d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:32:29.603028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}